PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic Osteomyelitis is a well-known clinical entity affecting patients holistically and presents with multiple treatment challenges. Local antibiotic delivery with biodegradable drug carriers has shown promising results.
UNASSIGNED: Prospective multicenter study performed at 2 centers from November 2021 to January 2023 on 95 osteomyelitis patients treated with surgical debridement & STIMULAN™ for local antibiotic delivery. Patients were randomized into 3 groups. Authors compared antibiotic combinations, bead quality, bead setting, and resorption time for calcium sulfate beads- STIMULAN™. Additionally, organisms isolated, WBC Turnover time, Hypersensitivity Reactions, Recurrence, and Revision Rates were documented.
UNASSIGNED: 95 patients underwent surgical debridement and STIMULAN™ bead application for chronic osteomyelitis. The proximal 1/3rd tibia was commonly affected. The most common symptoms were sinus and pus discharge in 96.84 % & 86.31 % of patients respectively (p < 0.001). Staphylococcus aureus & MRSA were isolated in 37.8 % & 29.4 % of the patient\'s wound culture respectively. Bead setting time in Descending order was Group 3 > Group 2 > Group 1 (p < 0.001). Bead setting first in Group 1 followed by Group 3 & 2. On compression, Group-1 beads withstood maximum compression forces & had smooth even bead surfaces. On radiographs, 1/3rd bead volume in ascending order was Group 3 > Group 2 > Group 1 (p < 0.001). 2/3rd reduction in ascending order was Group 3 > Group 2 > Group 1. Complete bead absorption was earliest seen in Group 3 followed by Group 2 & Group 1 (p < 0.001). Recurrence in 2 patients (Group 2) at 6 weeks. Revision rate: 2.10 %. There were no incidences of hypersensitivity. Suture removal was done at 16 ± 2 days.
UNASSIGNED: STIMULAN™ combination with tobramycin, vancomycin, and gentamycin is stable, and forms uniform beads with predictable drug elution & bead resorption with negligible side effects. A mixture with higher liquid content sets later, forms softer beads, and resorbs earlier.
UNASSIGNED: Prospective multicenter study performed at 2 centers from November 2021 to January 2023 on 95 osteomyelitis patients treated with surgical debridement & STIMULAN™ for local antibiotic delivery. Patients were randomized into 3 groups. Authors compared antibiotic combinations, bead quality, bead setting, and resorption time for calcium sulfate beads- STIMULAN™. Additionally, organisms isolated, WBC Turnover time, Hypersensitivity Reactions, Recurrence, and Revision Rates were documented.
UNASSIGNED: 95 patients underwent surgical debridement and STIMULAN™ bead application for chronic osteomyelitis. The proximal 1/3rd tibia was commonly affected. The most common symptoms were sinus and pus discharge in 96.84 % & 86.31 % of patients respectively (p < 0.001). Staphylococcus aureus & MRSA were isolated in 37.8 % & 29.4 % of the patient\'s wound culture respectively. Bead setting time in Descending order was Group 3 > Group 2 > Group 1 (p < 0.001). Bead setting first in Group 1 followed by Group 3 & 2. On compression, Group-1 beads withstood maximum compression forces & had smooth even bead surfaces. On radiographs, 1/3rd bead volume in ascending order was Group 3 > Group 2 > Group 1 (p < 0.001). 2/3rd reduction in ascending order was Group 3 > Group 2 > Group 1. Complete bead absorption was earliest seen in Group 3 followed by Group 2 & Group 1 (p < 0.001). Recurrence in 2 patients (Group 2) at 6 weeks. Revision rate: 2.10 %. There were no incidences of hypersensitivity. Suture removal was done at 16 ± 2 days.
UNASSIGNED: STIMULAN™ combination with tobramycin, vancomycin, and gentamycin is stable, and forms uniform beads with predictable drug elution & bead resorption with negligible side effects. A mixture with higher liquid content sets later, forms softer beads, and resorbs earlier.
摘要：
慢性骨髓炎是一种众所周知的临床实体，从整体上影响患者，并面临多种治疗挑战。使用可生物降解的药物载体的局部抗生素递送已显示出有希望的结果。
■从2021年11月至2023年1月在2个中心进行的前瞻性多中心研究，对象是95例接受手术清创和STIMULAN™治疗的骨髓炎患者，以进行局部抗生素治疗。患者随机分为3组。作者比较了抗生素组合，胎圈质量,胎圈设置,和硫酸钙珠的吸收时间-STIMULAN™。此外,分离的生物体，WBC周转时间,超敏反应,复发,并记录了修订率。
■95例慢性骨髓炎患者接受了手术清创和STIMULAN™磁珠应用。近端1/3胫骨通常受累。96.84%和86.31%的患者最常见的症状是鼻窦和脓液排出(p<0.001)。金黄色葡萄球菌和MRSA分别在37.8％和29.4％的患者伤口培养物中分离。按降序排列的珠凝固时间为第3组>第2组>第1组(p<0.001)。在第1组中首先设置珠子，然后是第3和2组。压缩时，第1组珠承受最大压缩力并具有光滑均匀的珠表面。在射线照片上，按升序排列的1/3珠体积为组3>组2>组1(p<0.001)。按升序排列的第2/3次减少是第3组>第2组>第1组。在组3中最早观察到完全的珠子吸收,随后是组2和组1(p<0.001)。2例患者（第2组）在6周复发。修订率：2.10%。没有发生超敏反应。在16±2天进行缝线移除。
■STIMULAN™与妥布霉素的组合，万古霉素,庆大霉素是稳定的，并形成具有可预测的药物洗脱和珠子吸收的均匀珠子，副作用可忽略不计。液体含量较高的混合物稍后凝固，形成较软的珠子，和早些时候的度假村。
■从2021年11月至2023年1月在2个中心进行的前瞻性多中心研究，对象是95例接受手术清创和STIMULAN™治疗的骨髓炎患者，以进行局部抗生素治疗。患者随机分为3组。作者比较了抗生素组合，胎圈质量,胎圈设置,和硫酸钙珠的吸收时间-STIMULAN™。此外,分离的生物体，WBC周转时间,超敏反应,复发,并记录了修订率。
■95例慢性骨髓炎患者接受了手术清创和STIMULAN™磁珠应用。近端1/3胫骨通常受累。96.84%和86.31%的患者最常见的症状是鼻窦和脓液排出(p<0.001)。金黄色葡萄球菌和MRSA分别在37.8％和29.4％的患者伤口培养物中分离。按降序排列的珠凝固时间为第3组>第2组>第1组(p<0.001)。在第1组中首先设置珠子，然后是第3和2组。压缩时，第1组珠承受最大压缩力并具有光滑均匀的珠表面。在射线照片上，按升序排列的1/3珠体积为组3>组2>组1(p<0.001)。按升序排列的第2/3次减少是第3组>第2组>第1组。在组3中最早观察到完全的珠子吸收,随后是组2和组1(p<0.001)。2例患者（第2组）在6周复发。修订率：2.10%。没有发生超敏反应。在16±2天进行缝线移除。
■STIMULAN™与妥布霉素的组合，万古霉素,庆大霉素是稳定的，并形成具有可预测的药物洗脱和珠子吸收的均匀珠子，副作用可忽略不计。液体含量较高的混合物稍后凝固，形成较软的珠子，和早些时候的度假村。
